<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03838887</url>
  </required_header>
  <id_info>
    <org_study_id>placental vascular indices</org_study_id>
    <nct_id>NCT03838887</nct_id>
  </id_info>
  <brief_title>Comparison Between Uterine Artery Doppler and Placental Vascular Indices in Prediction of Preeclampsia</brief_title>
  <official_title>Comparison Between Uterine Artery Doppler and Placental Vascular Indices in Prediction of Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Centre, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Centre, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      • Preeclampsia is a multisystem disorder that can cause considerable maternal and fetal&#xD;
      morbidity and mortality. Late preeclampsia (with delivery &gt;34 weeks) is more frequent and&#xD;
      less serious than early preeclampsia (with delivery &lt;34 weeks). Poor early placentation has&#xD;
      been especially associated with early disease. Early identification of women at risk of&#xD;
      preeclampsia is currently a crucial aim of antenatal care since they may benefit from&#xD;
      prophylactic treatment and increased surveillance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The introduction of three-dimensional (3D) ultrasound techniques, with the option of&#xD;
           calculating placental volume and measuring vascular indices, has created an excellent&#xD;
           opportunity to study early changes in the uteroplacental circulation space, which&#xD;
           includes the maternal spiral arteries and the intervillous space. This technology may&#xD;
           allow a more direct evaluation of the abnormal placentation process thought to herald&#xD;
           the development of preeclampsia.&#xD;
&#xD;
        -  The aim of this study was to assess the usefulness of placental volume and 3D vascular&#xD;
           indices as reliable predictors of early preeclampsia in comparison to uterine artery&#xD;
           Doppler&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>placental vascular indices in prediction of preeclampsia</measure>
    <time_frame>one year</time_frame>
    <description>placental vascular indices in prediction of preeclampsia compared to uterine artery doppler in prediction of preeclampsia</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>Pregnant women:&#xD;
Age between 18-35 years&#xD;
Parity: primigravidas and multiparas.&#xD;
Have no history of preeclampsia or eclampsia.&#xD;
Have no history of chronic hypertension.&#xD;
Not diabetic.&#xD;
Not have antiphospholipid syndrome.&#xD;
Not have autoimmune disease such as SLE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High risk group</arm_group_label>
    <description>Pregnant women with:&#xD;
History of preeclampsia -Eclapmsia&#xD;
Chronic hypertension&#xD;
Diabetic&#xD;
Antiphospholipid syndrome.&#xD;
Autoimmune syndrome such as SLE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ultrasound machine</intervention_name>
    <description>Ultrasound machine with a vocal software</description>
    <arm_group_label>High risk group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All pregnant women will be examined for antenatal care in the outpatient clinic and fetal&#xD;
        medicine unit of obstetrics and gynecology department then they will be divided into two&#xD;
        groups control and high risk&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A. Control group: Pregnant women:&#xD;
&#xD;
               1. Age between 18-35 years&#xD;
&#xD;
               2. Parity: primigravidas and multiparas.&#xD;
&#xD;
               3. Have no history of preeclampsia or eclampsia.&#xD;
&#xD;
               4. Have no history of chronic hypertension.&#xD;
&#xD;
               5. Not diabetic.&#xD;
&#xD;
               6. Not have antiphospholipid syndrome.&#xD;
&#xD;
               7. Not have autoimmune disease such as SLE.&#xD;
&#xD;
        B. High risk group: Pregnant women with:&#xD;
&#xD;
          1. History of preeclampsia -Eclapmsia&#xD;
&#xD;
          2. Chronic hypertension&#xD;
&#xD;
          3. Diabetic&#xD;
&#xD;
          4. Antiphospholipid syndrome.&#xD;
&#xD;
          5. Autoimmune syndrome such as SLE.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Smoking&#xD;
&#xD;
               -  Dichorionic placentae&#xD;
&#xD;
               -  Fetal anomaly&#xD;
&#xD;
               -  Uterine fibroid at the site of placental implantation&#xD;
&#xD;
               -  Subchorionic hematoma&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>examination of pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>SHERIF MOHAMMED ELSIRGANY, DOCTOR</last_name>
    <phone>+201223607191</phone>
    <email>SHERIFELSIRGANY@YAHOO.COM</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Research Centre</name>
      <address>
        <city>Cairo</city>
        <zip>1234</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SHERIF MOHAMMED ELSIRGANY, DOCTOR</last_name>
      <phone>+01223607191</phone>
      <email>SHERIFELSIRGANY@YAHOO.COM</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 3, 2019</study_first_submitted>
  <study_first_submitted_qc>February 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Centre, Egypt</investigator_affiliation>
    <investigator_full_name>Sherif Elsirgany</investigator_full_name>
    <investigator_title>Researcher ,Family Planning and Reproductive Health Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

